<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-03873R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002657</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry</subject><subject>Cell Biology</subject><subject>Evidence-Based Healthcare</subject><subject>Hematology</subject><subject>Oncology</subject><subject>Cell Biology/Cell Adhesion</subject><subject>Cardiovascular Disorders/Vascular Biology</subject></subj-group></article-categories><title-group><article-title>The CXC-Chemokine CXCL4 Interacts with Integrins Implicated in Angiogenesis</article-title><alt-title alt-title-type="running-head">CXCL4 Integrins Angiogenesis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aidoudi</surname><given-names>Sallouha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bujakowska</surname><given-names>Kinga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kieffer</surname><given-names>Nelly</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bikfalvi</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>INSERM, U920, Talence, France</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Univ Bordeaux, Talence, France</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Laboratoire de Biologie et Physiologie Int&#x000e9;gr&#x000e9;e (CNRS/GDRE-ITI), University of Luxembourg, Luxembourg City, Luxembourg</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zwaka</surname><given-names>Thomas</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Baylor College of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>salouaaidoudi@yahoo.fr </email> (SA); <email>a.bikfalvi@angio.u-bordeaux1.fr</email> (AB)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: SA AB. Performed the experiments: SA KB. Analyzed the data: SA AB. Contributed reagents/materials/analysis tools: AB NK. Wrote the paper: SA AB. Designed the study: SA.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>16</day><month>7</month><year>2008</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>e2657</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2008</year></date></history><copyright-statement>Aidoudi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><p>The human CXC-chemokine CXCL4 is a potent inhibitor of tumor-induced angiogenesis. Considering that CXCL4 is sequestered in platelet &#x003b1;-granules and released following platelet activation in the vicinity of vessel wall injury, we tested the hypothesis that CXCL4 might function as a ligand for integrins. Integrins are a family of adhesion receptors that play a crucial role in angiogenesis by regulating early angiogenic processes, such as endothelial cell adhesion and migration. Here, we show that CXCL4 interacts with &#x003b1;v&#x003b2;3 on the surface of &#x003b1;v&#x003b2;3-CHO. More importantly, human umbilical vein endothelial cells adhere to immobilized CXCL4 through &#x003b1;v&#x003b2;3 integrin, and also through other integrins, such as &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1. We further demonstrate that CXCL4-integrin interaction is of functional significance <italic>in vitro</italic>, since immobilized CXCL4 supported endothelial cell spreading and migration in an integrin-dependent manner. Soluble CXCL4, in turn, inhibits integrin-dependent endothelial cell adhesion and migration. As a whole, our study identifies integrins as novel receptors for CXCL4 that may contribute to its antiangiogenic effect.</p></abstract><counts><page-count count="14"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Angiogenesis is the formation of new capillaries from preexisting blood vessels. Angiogenesis plays an important role in physiologic processes such as wound healing and in disease progression such as cancer, diabetic retinopathy and various inflammatory disorders <xref ref-type="bibr" rid="pone.0002657-Folkman1">&#x0005b;1&#x0005d;</xref>. In particular, the expansion of solid tumors and other cancers critically depends on angiogenesis <xref ref-type="bibr" rid="pone.0002657-Folkman2">&#x0005b;2&#x0005d;</xref>, making anti-angiogenesis strategies relevant for cancer therapy <xref ref-type="bibr" rid="pone.0002657-Folkman3">&#x0005b;3&#x0005d;</xref>. CXCL4, a CXC-chemokine, is synthesized predominantly in megakaryocytes, sequestered in &#x003b1;-granules of platelets, and released upon activation of platelets <xref ref-type="bibr" rid="pone.0002657-Levine1">&#x0005b;4&#x0005d;</xref>. CXCL4 and the peptide derived from its carboxyl-terminal domain (CXCL4/CTF) display a strong antiangiogenic activity <italic>in vitro</italic><xref ref-type="bibr" rid="pone.0002657-Maione1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref> and <italic>in vivo</italic><xref ref-type="bibr" rid="pone.0002657-Maione1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Sharpe1">&#x0005b;8&#x0005d;</xref>. They suppress growth of various tumors <xref ref-type="bibr" rid="pone.0002657-Tanaka1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Bello1">&#x0005b;11&#x0005d;</xref> and metastasis <xref ref-type="bibr" rid="pone.0002657-Kolber1">&#x0005b;12&#x0005d;</xref><italic>in vivo</italic>. This effect is related to their antiangiogenic action and not to tumor cell proliferation <xref ref-type="bibr" rid="pone.0002657-Sharpe1">&#x0005b;8&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Kolber1">&#x0005b;12&#x0005d;</xref>. Although CXCL4 is one of the first agents discovered to have an antiangiogenic action in ex-<italic>vivo</italic> systems <xref ref-type="bibr" rid="pone.0002657-Maione1">&#x0005b;5&#x0005d;</xref>, the specific receptor mechanisms that transduce the antiangiogenic signal of CXCL4 are still poorly understood.</p><p>Angiogenesis depends on vascular endothelial cell proliferation, migration and invasion. A family of adhesion receptors known as integrin receptors tightly regulates these early angiogenic processes. Indeed, integrins are the major adhesion receptors used by endothelial cells undergoing angiogenesis to interact with their extracellular matrix (ECM). This interaction causes spreading of endothelial cells with cytoskeleton re-organization events necessary for cells to invade ECM, to proliferate, to migrate and to ultimately form new tubular vessels <xref ref-type="bibr" rid="pone.0002657-Davis1">&#x0005b;13&#x0005d;</xref>. The integrin-dependency of tumor angiogenesis <italic>in vivo</italic> is evidenced by the fact that antagonists of the &#x003b1;v&#x003b2;3 integrin, which are highly expressed in angiogenic endothelium, suppress tumor growth by inhibiting angiogenesis <xref ref-type="bibr" rid="pone.0002657-Brooks1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Brooks2">&#x0005b;15&#x0005d;</xref>. Furthermore, the functionally and structurally homologous &#x003b1;v&#x003b2;5 has been implicated in angiogenesis under certain conditions and selective antagonists of &#x003b1;v&#x003b2;5 or dual antagonists of &#x003b1;v&#x003b2;3 and &#x003b1;v&#x003b2;5 integrins inhibit VEGF-stimulated angiogenesis <italic>in vivo</italic> in animal models <xref ref-type="bibr" rid="pone.0002657-Friedlander1">&#x0005b;16&#x0005d;</xref>. Finally, the &#x003b1;5&#x003b2;1 integrin was shown to play a crucial role in angiogenesis and selective antagonists of &#x003b1;5&#x003b2;1 integrin block tumor angiogenesis, thereby causing regression of human tumors in animal models <xref ref-type="bibr" rid="pone.0002657-Kim1">&#x0005b;17&#x0005d;</xref>. Several integrin inhibitors are currently tested as therapeutics for cancer <xref ref-type="bibr" rid="pone.0002657-Folkman3">&#x0005b;3&#x0005d;</xref>.</p><p>Taking into account that CXCL4 is released from the &#x003b1;-granules of activated platelets in the vicinity of vessel wall injury <xref ref-type="bibr" rid="pone.0002657-Fukami1">&#x0005b;18&#x0005d;</xref> and that CXCL4 targets the endothelial cells <italic>in vivo</italic> that undergo active angiogenesis <xref ref-type="bibr" rid="pone.0002657-Hansell1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Borgstrom1">&#x0005b;20&#x0005d;</xref>, we examined the possibility that CXCL4 might function as a ligand for integrins. We show here that CXCL4 binds to &#x003b1;v&#x003b2;3 and to some extent to &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 integrins on the surface of endothelial cells. The CXCL4-integrin interaction is of functional significance, since CXCL4 modulated endothelial cell functions, such as spreading and migration through integrins. Taken together with the established importance of integrin in tumor angiogenesis, this study provides a new mechanistic context for the function of CXCL4 as an angiogenesis inhibitor.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>1/Immobilized CXCL4 or CXCL4/CTF induces human endothelial cell spreading, and focal adhesion kinase (FAK) phosphorylation</title><p>Integrin-mediated cell attachment on cognate integrin ligands, such as ECM proteins, results in cell spreading, focal adhesion formation, and tyrosine phosphorylation of intracellular proteins <xref ref-type="bibr" rid="pone.0002657-Schwartz1">&#x0005b;21&#x0005d;</xref>. When integrin inhibitors such as antibodies are immobilized on a substrate, they act as agonist and similarly activate intracellular events <xref ref-type="bibr" rid="pone.0002657-Leavesley1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Stromblad1">&#x0005b;23&#x0005d;</xref>. To examine whether immobilized CXCL4 would function as an integrin agonist, HUVECs were plated on coverslips that had been coated with CXCL4. As shown in <xref ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>, immobilized CXCL4 similar to natural integrin ligands fibrinogen or fibronectin, promoted endothelial cells spreading, focal adhesion and stress fibers formation. Furthermore, to determine whether the C-terminus of CXCL4 exhibited similar effects, we used a synthetic peptide encompassing amino-acid sequence 47&#x02013;70 (CXCL4/CTF). Previous data showed that the peptide retains full anti-angiogenic activity of CXCL4 <xref ref-type="bibr" rid="pone.0002657-Maione1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref>. As shown in <xref ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>, CXCL4/CTF demonstrated similar effects on endothelial cell spreading, focal adhesion and stress fibers formation as full length CXCL4. Furthermore, when HUVECs are plated on a &#x02013;scrambled peptide containing amino acides derived from CXCL4/CTF (CXCL4/CTF-S) (that does not exhibit anti-angiogenic activity), or on polylysine (to which cells adhere in an integrin-independent manner), they remained round, and failed to spread and to induce focal adhesion formation (<xref ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>).</p><fig id="pone-0002657-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g001</object-id><label>Figure 1</label><caption><title>Immobilized CXCL4 or CXCL4/CTF promotes human umbilical vein endothelial cells (HUVECs) spreading, focal adhesion and stress fiber formation.</title><p>(A) Analysis of spreading, focal adhesion and stress fibers. HUVECs were plated for 4h on coverslips that had been coated with (25 &#x000b5;g/ml) CXCL4, (25 &#x000b5;g/ml) CXCL4/CTF, (100 &#x000b5;g/ml) fibrinogen, (25 &#x000b5;g/ml), CXCL4/CTF-S and (100 &#x000b5;g/ml) poly-D-lysine. After washing, the cells are fixed. The degree of cell spreading is seen from the phase contrast micrographs (left side) Then the cells were permeabilized and stained to visualize focal adhesion (vinculin staining, green), and actin stress fibers (Rhodamin-Phalloidin staining, red) by confocal microscopy (right side). (B) Analysis of tyrosine phosphorylation of FAK. Effect of HUVEC cell adhesion to CXCL4 or CXCL4/CTF on tyrosine phosphorylation of FAK. HUVECs were maintained in suspension for 60 min (BSA, lane 1) or allowed to attach to integrins ligand (fibrinogen, lane 4) or CXCL4 (lane 2) or CXCL4/CTF (lane 3). Cells lysates containing equal amounts of protein were immunoprecipitated with anti-FAK antibody. One half of immunoprecipitates was subjected to immunoblotting with anti-phosphotyrosine mAbs, 4G10, and PY20, and the other half was probed with mAb anti-FAK.</p></caption><graphic xlink:href="pone.0002657.g001"/></fig><p>Focal adhesion kinase (FAK) is a 125 kDa cytoplasmic tyrosine kinase colocalised with integrins at focal adhesion contacts and rapidly becomes phosphorylated and activated upon integrin mediated cell adhesion. As shown above, immobilized CXCL4 or CXCL4/CTF promotes cell spreading with focal adhesion formation (<xref ref-type="fig" rid="pone-0002657-g001">Fig. 1A</xref>). We tested whether these events are sufficient to activate (tyrosine phosphorylation) FAK. As shown in (<xref ref-type="fig" rid="pone-0002657-g001">Fig. 1B</xref>), attachment of HUVECs to immobilized CXCL4 or CXCL4/CTF, similar to fibronectin, induced tyrosine phosphorylation of FAK. As expected, attached cell to polylysine, similar to cells in suspension, failed to tyrosine phosphorylate FAK. Taken together, these results suggest that immobilized CXCL4 or CXCL4/CTF serves as an adhesive ligand to endothelial cells and activates postligand binding events downstream of integrins.</p></sec><sec id="s2b"><title>2/CXCL4 or CXCL4/CTF mediates &#x003b1;v&#x003b2;3-CHO cell adhesion through &#x003b1;v&#x003b2;3 integrins</title><p>&#x003b1;v&#x003b2;3 is expressed on activated endothelial cells. In addition, inhibition of &#x003b1;v&#x003b2;3 by selective antagonists blocks angiogenesis in response to growth factors in several tumor models <xref ref-type="bibr" rid="pone.0002657-Hsu1">&#x0005b;24&#x0005d;</xref>, indicating that this integrin plays an essential role in tumor growth dependent on angiogenesis. Thus, for all these reasons, we first sought to test the role of &#x003b1;v&#x003b2;3 integrin as a putative receptor to the antiangiogenic factor, CXCL4 and its derived peptide. For this purpose, we used a CHO cells transfected with &#x003b1;v&#x003b2;3 (&#x003b1;v&#x003b2;3-CHO, clone A06) and mock-transfected CHO cells. First, we verified &#x003b1;v&#x003b2;3 expression by flow cytometry using a monoclonal antibody specific for the human &#x003b1;v&#x003b2;3 (LM609). In accordance with our previous data <xref ref-type="bibr" rid="pone.0002657-Pasco1">&#x0005b;<italic>25</italic>&#x0005d;</xref>, &#x003b1;v&#x003b2;3 integrin is highly expressed in &#x003b1;v&#x003b2;3-CHO cells whereas control mock-transfected CHO cells are negative for &#x003b1;v&#x003b2;3 expression (data not shown).</p><sec id="s2b1"><title>Immobilized CXCL4 or CXCL4/CTF supported &#x003b1;v&#x003b2;3-CHO but not CHO adhesion, in a saturable and concentration-dependent manner</title><p>Quantitative cell attachment assays demonstrated that immobilized CXCL4 or CXCL4/CTF supported &#x003b1;v&#x003b2;3<bold>-</bold>CHO cell adhesion, but not mock-transfected CHO cells, in a saturable and concentration-dependent manner (<xref ref-type="fig" rid="pone-0002657-g002">Fig. 2A</xref>). Also, as shown in <xref ref-type="fig" rid="pone-0002657-g002">Fig 2B</xref>, adhesion to CXCL4 or CXCL4/CTF was significantly inhibited by monoclonal antibodies LM609, AV1 and B3A against &#x003b1;v&#x003b2;3, &#x003b1;v and &#x003b2;3, respectively. These results demonstrate that &#x003b1;v&#x003b2;3<bold>-</bold>CHO adhesion on immobilized CXCL4 or CXCL4/CTF is mediated by &#x003b1;v&#x003b2;3 integrin. Consistent with these results, addition of 10 mM of EDTA, a strong inhibitor of divalent cation-dependent cell integrin receptors, blocks the adhesion of &#x003b1;v&#x003b2;3<bold>-</bold>CHO cells to CXCL4 or CXCL4/CTF (<xref ref-type="fig" rid="pone-0002657-g002">Fig. 2B</xref>). Furthermore, the incubation of cells with two well established cation activators integrins, Mn2&#x0002b; and Mg2&#x0002b; <xref ref-type="bibr" rid="pone.0002657-Humphries1">&#x0005b;26&#x0005d;</xref>, prior to adhesion of cells to immobilized CXCL4 or CXCL4/CTF enhances the cell attachment about 25&#x00025; (<xref ref-type="fig" rid="pone-0002657-g002">Fig. 2C</xref>). These findings indicate that immobilized CXCL4 or CXCL4/CTF mediates &#x003b1;v&#x003b2;3<bold>-</bold>CHO cell adhesion in a divalent cation-dependent manner. As with EDTA, addition of RGD-peptides blocks the adhesion of &#x003b1;v&#x003b2;3<bold>-</bold>CHO to CXCL4 or CXCL4/CTF, whereas control RGE peptide had no affect on adhesion (<xref ref-type="fig" rid="pone-0002657-g002">Fig. 2B</xref>). These findings suggest that the interaction of &#x003b1;v&#x003b2;3<bold>-</bold>CHO cells with CXCL4 or -CXCL4/CTF is RGD-dependent. This is consistent with the idea that &#x003b1;v&#x003b2;3 integrin is a CXCL4 receptor in &#x003b1;v&#x003b2;3<bold>-</bold>CHO cells, since &#x003b1;v&#x003b2;3 is RGD dependent. Taken together, these results demonstrate that &#x003b1;v&#x003b2;3<bold>-</bold>CHO cells attachment on immobilized CXCL4 or CXCL4/CTF is a cation-dependent process and is &#x003b1;v&#x003b2;3 integrin mediated.</p><fig id="pone-0002657-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g002</object-id><label>Figure 2</label><caption><title>CXCL4 or CXCL4/CTF mediates &#x003b1;v&#x003b2;3-CHO cell adhesion through &#x003b1;v&#x003b2;3 integrins.</title><p>In A. Dose dependence of &#x003b1;v&#x003b2;3-CHO cell adhesion to CXCL4 or CXCL4/CTF. &#x003b1;v&#x003b2;3-CHO and mock-transfected CHO were plated onto microtiter wells coated with the indicated concentrations of CXCL4 or CXCL4/CTF and cell attachment was analyzed as described in <xref ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref>. In B, &#x003b1;v&#x003b2;3-CHO adhesion to CXCL4 or CXCL4/CTF is &#x003b1;v&#x003b2;3 integrin-dependent. Cells were incubated with the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or CXCL4/CTF. Anti-integrin antibodies used were: anti-&#x003b1;v&#x003b2;3 (LM609), anti-&#x003b1;v (&#x00391;V1), anti-&#x003b2;3 (B3A). Cell attachment was analyzed as above. Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.001; &#x0002a;&#x0002a;, P&#x02264;0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n&#x0200a;&#x0003d;&#x0200a;4 independent experiments. In C, adhesion of &#x003b1;v&#x003b2;3-CHO to immobilized CXCL4 or CXCL4/CTF is cation-dependent manner. The serum free medium used for the adhesion assay contained 0.25 mM of Mn2&#x0002b;, or 2 mM of Mg2&#x0002b;. Cell attachment was analyzed as above. Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.005 compared to CXCL4 or CXCL4/CTF alone; n&#x0200a;&#x0003d;&#x0200a;4 independent experiments.</p></caption><graphic xlink:href="pone.0002657.g002"/></fig></sec><sec id="s2b2"><title>CXCL4 and CXCL4/CTF bind to purified integrins</title><p>To reinforce the results described above, we studied the direct interaction of CXCL4, or CXCL4/CTF, to integrin in a solid-phase ligand binding assay <xref ref-type="bibr" rid="pone.0002657-Rehn1">&#x0005b;27&#x0005d;</xref> using a purified human integrin &#x003b1;v&#x003b2;3 <bold>(</bold>protein). As shown in <xref ref-type="fig" rid="pone-0002657-g003">Fig. 3A</xref>, soluble &#x003b1;v&#x003b2;3 demonstrates a concentration- dependent and saturable binding to immobilized CXCL4 or its peptide CXCL4/CTF. The specificity of the interaction was confirmed by inhibition of CXCL4 or CXCL4/CTF binding to &#x003b1;v&#x003b2;3 integrin with the inhibitory &#x003b1;v (AV1) and &#x003b2;3 (B3A) antibodies, as well with RGD peptides (<xref ref-type="fig" rid="pone-0002657-g003">Fig. 3B</xref>). Thus, these results demonstrate a specific and direct interaction between the angiogenic inhibitor CXCL4 or its peptide CXCL4/CTF with the &#x003b1;v&#x003b2;3 integrin.</p><fig id="pone-0002657-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g003</object-id><label>Figure 3</label><caption><title>CXCL4 or CXCL4/CTF binds to purified &#x003b1;v&#x003b2;3 integrins in a concentration-dependent and specific manners in solid-phase ligand binding assay.</title><p>&#x00391;. &#x003b1;v&#x003b2;3 integrin was added to wells coated with CXCL4 or CXCL4/CTF as indicated, and incubated overnight at 4&#x000b0;C. Anti-&#x003b1;v, peroxidase-conjugated anti-rabbit IgG antibodies, and TMB substrate were used to detect bound integrin. B. Soluble RGD-, RGE peptides or inhibitory anti-integrin antibodies were added to block the interaction between CXCL4 or CXCL4/CTF and &#x003b1;v&#x003b2;3 integrin. Bound integrin was detected as above. Anti-integrin antibodies used were: anti-&#x003b1;v (AV1) and anti-&#x003b2;3 (B3A). Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.005; &#x0002a;&#x0002a;, P&#x02264;0,0005 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n&#x0200a;&#x0003d;&#x0200a;3 independent experiments.</p></caption><graphic xlink:href="pone.0002657.g003"/></fig></sec><sec id="s2b3"><title>Immobilized CXCL4 or CXCL4/CTF promotes &#x003b1;v&#x003b2;3-CHO cell spreading</title><p>Confocal analysis showed that immobilized CXCL4 or CXCL4/CTF promoted &#x003b1;v&#x003b2;3-CHO cell spreading, focal adhesion and stress fibers formation (<xref ref-type="fig" rid="pone-0002657-g004">Fig. 4</xref>). These events were blocked in presence of EDTA or RGD peptides or with antibodies against &#x003b1;v&#x003b2;3. In contrast, mock-transfected CHO cells did not appreciably spread and generate stress fibers of actin on CXCL4 or CXCL4/CTF. In addition, when &#x003b1;v&#x003b2;3-CHO cells are plated on a scrambled peptide derived (CXCL4CTF-S), or on polylysine, they remained round, and failed to spread and to induce focal adhesion formation (<xref ref-type="fig" rid="pone-0002657-g004">Fig. 4</xref>). These results indicate that immobilized CXCL4 or CXCL4/CTF induces &#x003b1;v&#x003b2;3-CHO cell spreading through &#x003b1;v&#x003b2;3 integrins. Collectively, these results show that CXCL4 or CXCL4/CTF interacts with &#x003b1;v&#x003b2;3 integrins and activates postligand binding event downstream to integrins, such as cell spreading.</p><fig id="pone-0002657-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g004</object-id><label>Figure 4</label><caption><title>Immobilized CXCL4 or CXCL4/CTF promotes &#x003b1;v&#x003b2;3-CHO cell spreading, focal adhesion and stress fiber formation.</title><p>A. &#x003b1;v&#x003b2;3-CHO and mock-transfected CHO cells were plated for 4 h on coverslips that had been coated with (25 &#x000b5;g/ml) CXCL4, (25 &#x000b5;g/ml) CXCL4/CTF, (25 &#x000b5;g/ml) CXCL4/CTF-S, (100 &#x000b5;g/ml) fibrinogen and (100 &#x000b5;g/ml) poly-D-lysine. After washing, the cells are fixed. The degree of cell spreading is seen from the phase contrast micrographs (left side). Then the cells were permeabilized and stained to visualize focal adhesion (vinculin staining, green), and actin stress fibers (Rhodamin-Phalloidin staining, red) by confocal microscopy (right side). B. Effects of function-blocking anti-integrin antibodies and EDTA and RGD-, RGE-peptides on cell spreading to CXCL4 or CXCL4/CTF. &#x003b1;v&#x003b2;3-CHO cells were incubated with 10 mM EDTA or 25 &#x000b5;g/ml of RGD- or RGE-peptides or 10 &#x000b5;g/ml anti-&#x003b1;v&#x003b2;3 (LM609), before plating to coverslips coated with (25 &#x000b5;g/ml) CXCL4 or (25 &#x000b5;g/ml) CXCL4/CTF for 3 h at 37&#x000b0;C. Wells were washed with PBS, and cells were photographed.</p></caption><graphic xlink:href="pone.0002657.g004"/></fig></sec></sec><sec id="s2c"><title>3/Human endothelial cells (HUVECS) adhere on immobilized CXCL4-, or CXCL4/CTF- through &#x003b1;v&#x003b2;3, and additional integrins, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1</title><p>To investigate the interaction of CXCL4 or CXCL4/CTF with endogenous integrins, we tested the interaction of CXCL4 or CXCL4/CTF with integrins expressed on the surface of cultured HUVECs. We first screened the expression of endogenous integrins using a flow cytometry analysis. Accordingly with previous data <xref ref-type="bibr" rid="pone.0002657-Trikha1">&#x0005b;28&#x0005d;</xref>, we found that &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 were constitutively expressed on HUVECs cells using anti-human integrin antibodies specific for human integrin antibodies specific for &#x003b1;v&#x003b2;3 (LM609), &#x003b1;v&#x003b2;5 (P1F6), and &#x003b1;5&#x003b2;1 (HA5) (<xref ref-type="fig" rid="pone-0002657-g005">Fig. 5A</xref>). We next studied whether &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 integrins expressed on HUVECs could bind to CXCL4 or CXCL4/CTF. As shown in <xref ref-type="fig" rid="pone-0002657-g005">Fig. 5B</xref>, immobilized CXCL4 or CXCL4/CTF supported HUVECs cell adhesion in a saturable and concentration-dependent manner. Adhesion to CXCL4 or CXCL4/CTF was blocked in presence of RGD peptides or with antibodies against &#x003b1;v&#x003b2;3, thus confirming as above, that human endothelial cells adhere to immobilized CXCL4 or CXCL4/CTF through &#x003b1;v&#x003b2;3 integrins in an RGD dependent manner (<xref ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>). Interestingly, blocking antibodies against &#x003b1;v&#x003b2;5 (P1F6) and &#x003b1;5&#x003b2;1 (JBS5), as with &#x003b1;v&#x003b2;3, significantly reduced the adhesion of HUVECs cells on immobilized CXCL4 or CXCL4/CTF (<xref ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>). In contrast, blocking antibody against &#x003b1;2&#x003b2;1-integrin did not affect cell adhesion on immobilized CXCL4 or CXCL4/CTF (data not shown). Thus, these results demonstrate that endothelial cells adhere to immobilized CXCL4 or CXCL4/CTF through &#x003b1;v&#x003b2;3, and other integrins, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1, which play a crucial role in angiogenesis.</p><fig id="pone-0002657-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g005</object-id><label>Figure 5</label><caption><title>CXCL4-, or CXCL4/CTF-integrin mediates HUVECs adhesion through endogen &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 integrins.</title><p>A. Expression profile of integrins in HUVECs cells analyzed by flow cytometry. HUVECs were incubated with primary antibodies specific for &#x003b1;v&#x003b2;3 (LM609), or &#x003b1;v&#x003b2;5 (P1F6), or &#x003b1;5&#x003b2;1 (HA5) and antibody binding was detected with FITC-labeled secondary antibody as described under <xref ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref>. Cells stained with secondary antibody (2&#x000b0; Ab) only were used as a negative control. B. Dose dependence of HUVECs cell adhesion to CXCL4 or CXCL4/CTF. HUVECs were plated onto microtiter wells coated with the indicated concentrations of CXCL4 or CXCL4/CTF and cell attachment was analyzed as described in <xref ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref> C. Cell adhesion to CXCL4 and CXCL4/CTF is &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 integrins dependent. Cells were incubated with the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or CXCL4/CTF. Anti-integrin antibodies used were: anti-&#x003b1;v&#x003b2;3 (LM609), anti-&#x003b1;v (&#x00391;V1), anti-&#x003b2;3 (B3A), anti-&#x003b1;v&#x003b2;5 (P1F6), anti-&#x003b1;5&#x003b2;1 (JBS5), anti-&#x003b1;5 (P1D6) and anti-&#x003b2;1 (CD29). Cell attachment was analyzed as above. Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.001; &#x0002a;&#x0002a;, P&#x02264;0,0001; #, P&#x02264;0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n&#x0200a;&#x0003d;&#x0200a;4 independent experiments.</p></caption><graphic xlink:href="pone.0002657.g005"/></fig></sec><sec id="s2d"><title>4/Integrin agonists, Mn2&#x0002b; and PMA, enhance cell spreading, with focal adhesion and stress fibers formation, on immobilized CXCL4 or CXCL4/CTF</title><p>To further examine the postligand events downstream to integrins induced by immobilized CXCL4 or CXCL4/CTF, we examined in more detail cell spreading. As shown above, confocal analysis shows that immobilized CXCL4 or CXCL4/CTF promoted cell spreading, focal adhesion and stress fibers formation (<xref ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>,<xref ref-type="fig" rid="pone-0002657-g004">4</xref>). When the number of cells spread on different immobilized substrates was quantified, we found that immobilized CXCL4 or CXCL4/CTF promoted cell spreading by about 50 to 60&#x00025; in the absence of integrin agonists. When we analyzed the spreaded cells by confocal microscopic we found that around 40&#x00025; of these cells spread on CXCL4 or CXCL4/CTF (versus 60&#x00025; with fibronectin, data not shown) presented focal adhesions with stress fiber formation (<xref ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>). These events were significantly increased (from 40&#x00025; to 60&#x00025;) when we added two-well known integrin activators, extracellular (Mn2&#x0002b;) and intracellular (Phorbol 12-Mryristate 13 Acetate (PMA) agonists (<xref ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>). These agonists activate &#x003b1;v&#x003b2;3 integrin (convert &#x003b1;v&#x003b2;3 to a high-affinity conformation) and stimulate &#x003b1;v&#x003b2;3 functions <xref ref-type="bibr" rid="pone.0002657-Pampoori1">&#x0005b;29&#x0005d;</xref>, such spreading cells, as well as that of other integrins <xref ref-type="bibr" rid="pone.0002657-Vuori1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Mould1">&#x0005b;31&#x0005d;</xref>. Incubation of cells with 250 &#x000b5;M of Mn2&#x0002b; or 100 nM of PMA produced an increase in both the number of attached cells and in cell spreading of about 25&#x00025; and 30&#x00025; respectively (<xref ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>). This enhancement was completely blocked by adding EDTA or RGD (data not shown). This finding suggests that the interaction of CXCL4 or CXCL4/CTF to integrins, similar to natural integrin ligands, is subject to integrin function regulation such as affinity modulation (<italic>see</italic><xref ref-type="sec" rid="s3"><italic>Discussion</italic></xref>).</p><fig id="pone-0002657-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g006</object-id><label>Figure 6</label><caption><title>Integrin agonists, Mn2&#x0002b; and PMA, enhance cell spreading, with focal adhesion and stress fiber formation, on immobilized CXCL4 or CXCL4/CTF A, B.</title><p>a. Phase contrast analysis show an enhance of the number of &#x003b1;v&#x003b2;3-CHO and HUVECs spreading on immobilized CXCL4 or CXCL4/CTF, upon stimulation with Mn2&#x0002b; or PMA, b. Confocal analysis show an increase of the number of cell spreading with focal adhesion (Vinculin staining, green) and stress fibers (Rhodamin-Phalloidin staining, Red) formation in &#x003b1;v&#x003b2;3-CHO and HUVECs spread on immobilized CXCL4 or CXCL4/CTF treated with integrin stimulators, Mn2&#x0002b; or PMA, as compared with no agonists. C. 100 adherent cells on different substrat were scored for focal adhesions and stress fibers by two independent observers. Data are the means&#x000b1;SEM of 4 separate experiments. Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.005 compared to CXCL4 or CXCL4/CTF in the absence of integrin agonists.</p></caption><graphic xlink:href="pone.0002657.g006"/></fig></sec><sec id="s2e"><title>5/The ability of CXCL4 to bind to integrin is related to its anti-angiogenic action</title><p>The scrambled control peptide CXCL4/CTF-S fails to inhibit endothelial cell proliferation <xref ref-type="bibr" rid="pone.0002657-Lozano1">&#x0005b;32&#x0005d;</xref>. We thus tested whether this inactive peptide could bind to integrins. We found that, in contrast with CXCL4/CTF and similar to polylysine, &#x003b1;v&#x003b2;3-CHO or HUVECs plated on immobilized CXCL4/CTF-S peptide did not adhere significantly. Cells remained round and failed to assemble focal adhesion and to induce stress fibers (<xref ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>,<xref ref-type="fig" rid="pone-0002657-g004">4</xref>). The addition of the two integrin activators, Mn2&#x0002b; and PMA, had no effect on the number of attached cells or on cell spreading on PF-4/CTF-S as shown by confocal analysis (<xref ref-type="fig" rid="pone-0002657-g006">Fig. 6C</xref>). These results suggest that the ability of CXCL4 and CXCL4/CTF to bind integrins is correlated with their anti-angiogenic activity.</p></sec><sec id="s2f"><title>6/Soluble CXCL4 or CXCL4/CTF inhibits cell adhesion to immobilized fibronectin and vitronectin</title><p>To investigate whether CXCL4 or CXCL4/CTF could inhibits cell adhesion to integrin ligands, we tested the effect of soluble CXCL4 or CXCL4/CTF on &#x003b1;v&#x003b2;3-CHO and HUVECs cells adhesion to specific &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 ligands, vitronectin and fibronectin respectively. We found that the pre-incubation of cells with soluble CXCL4 or CXCL4/CTF induces cell rounding, and significantly inhibits cell adhesion to immobilized fibronectin and vitronectin, in a concentration-dependent manner (<xref ref-type="supplementary-material" rid="pone.0002657.s001">Fig. S1</xref>). CXCL4 or CXCL4/CTF did not affect cell adhesion to collagen I (data not shown). These results suggest that soluble CXCL4 and CXCL4/CTF act as antagonists of &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 integrins to their ligands.</p></sec><sec id="s2g"><title>7/immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin-dependent and -specific manners</title><p>Cell migration is an essential step in the angiogenesis process <xref ref-type="bibr" rid="pone.0002657-Davis1">&#x0005b;13&#x0005d;</xref>. Previous studies showed that CXCL4 or CXCL4/CTF block endothelial cell migration in response to FGF-2 or VEGF in stimulation <italic>in vitro</italic><xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Yoshida1">&#x0005b;33&#x0005d;</xref>, a process thought to mediate the anti-angiogenic effect of CXCL4 <italic>in vivo</italic>. On the other hand, &#x003b1;v&#x003b2;3 <xref ref-type="bibr" rid="pone.0002657-Byzova1">&#x0005b;34&#x0005d;</xref>, and &#x003b1;5&#x003b2;1 <xref ref-type="bibr" rid="pone.0002657-Kim1">&#x0005b;17&#x0005d;</xref> integrins have a crucial role in cell migration during angiogenesis. Taking into account our findings, we determined whether CXCL4 and its antiangiogenic derived peptide modulates endothelial cell migration through &#x003b1;v&#x003b2;3 and/or &#x003b1;5&#x003b2;1 integrins. Our finding showed that soluble CXCL4 or CXCL4/CTF inhibited HUVECs cells migration through fibronectin a reported &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 ligand <xref ref-type="bibr" rid="pone.0002657-Davis1">&#x0005b;13&#x0005d;</xref>, toward VEGF, in a dose depending manner (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7A</xref>). This migration is similarly inhibited by adding RGD peptides or by the blocking integrin antibodies, anti-&#x003b1;v&#x003b2;3 LM609 or anti-&#x003b1;5&#x003b2;1 JBS5 (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7A</xref>). These results are consistent with previous data <xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Yoshida1">&#x0005b;33&#x0005d;</xref>, and suggest that CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin dependent manner.</p><fig id="pone-0002657-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002657.g007</object-id><label>Figure 7</label><caption><title>Immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits integrin-dependent endothelial cell migration.</title><p>A. Soluble CXCL4 or CXCL4/CTF inhibits migration on fibronectin toward VEGF (5 ng/ml). HUVECs migration was determined in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S or 25 &#x000b5;g/ml of RGD-, RGE peptides or 10 &#x000b5;g/ml of anti-integrin antibodies (anti-&#x003b1;v; AV1 and anti-&#x003b1;5&#x003b2;1; JBS5) as described in <xref ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref>. Relative cell migration is indicated, each value is a mean&#x000b1;SEM from 3 independent experiments. Error bars represent the mean&#x000b1;SD, <sup>#</sup>, P&#x02264;0.05; &#x0002a;, P&#x02264;0.005, &#x0002a;&#x0002a;, P&#x02264;0.001 compared to the number of cell migrated in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides. B. Immobilized CXCL4 or CXCL4/CTF supports HUVECs migration in &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 integrins-dependent manner. Cell migration assay was performed on immobilized CXCL4 or CXCL4/CTF in serum free medium and in the presence or absence of inhibitory anti-integrin antibodies or RGD-, RGE peptides. The results at each point are the mean cell number of 10 randomly selected high magnification microscopic fields. Error bars represent the mean&#x000b1;SD, &#x0002a;, P&#x02264;0.005; &#x0002a;, P&#x02264;0.001 compared to CXCL4 or CXCL4/CTF in the presence of IgG control antibody; n&#x0200a;&#x0003d;&#x0200a;3 independent experiments. C. Soluble CXCL4 or CXCL4/CTF inhibits migration on fibronectin. HUVECs migration was determined in serum free medium and in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S or inhibitory anti-integrin antibodies or RGD-, RGE peptides. Relative cell migration is indicated, each value is a mean&#x000b1;SEM from 3 independent experiments. Error bars represent the mean&#x000b1;SD, <sup>#</sup>, P&#x02264;0.005; &#x0002a;, P&#x02264;0.001 compared to the number of cell migrated in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides.</p></caption><graphic xlink:href="pone.0002657.g007"/></fig><p>To study the functional significance of the specific CXCL4-integrin interaction, we examined the capacity of CXCL4 to modulate cells functions under conditions in which these functions are strictly dependent on integrins, and not any other agents. For this purpose, we use a haptotactic Boyden chamber assay to assess cell migration in the absence of growth factors, or other soluble chemoattractants (such as VEGF). Using this assay, previous data showed that immobilized integrin inhibitors act as functional agonists and similarly promote integrin functions as cell migration <xref ref-type="bibr" rid="pone.0002657-Leavesley1">&#x0005b;22&#x0005d;</xref>. On the other hand, cell migration is efficiently inhibited by the same integrin inhibitors when given in solution to the cells <xref ref-type="bibr" rid="pone.0002657-Leavesley1">&#x0005b;22&#x0005d;</xref>. We demonstrated that CXCL4 or CXCL4/CTF is similarly capable of modulating endothelial cell migration. Thus, HUVEC cells under serum free-medium migrated in a haptotactic Boyden chamber assay through a CXCL4- or CXCL4/CTF-coated membrane and this migration was significantly inhibited by RGD peptides or by the blocking integrin antibodies, anti-&#x003b1;v&#x003b2;3 LM609 or anti-&#x003b1;5&#x003b2;1 JBS5 (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7B</xref>). In control experiments, blocking antibody against &#x003b1;2&#x003b2;1-integrin did not affect cell migration through CXCL4- or CXCL4/CTF-coated membrane (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7B</xref>). Soluble CXCL4 or CXCL4/CTF, in turn, interferes with integrin-dependent cell migration. As shown in (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7C</xref>), soluble CXCL4 or CXCL4/CTF, but not the inactive peptide CXCL4/CTF-S, inhibited cell migration on immobilized fibronectin, in a concentration-dependent manner. In control experiments, RGD peptides or blocking antibodies against &#x003b1;v or &#x003b1;5&#x003b2;1&#x02212;integrin inhibited endothelial cell motility on fibronectin (<xref ref-type="fig" rid="pone-0002657-g007">Fig. 7C</xref>). Soluble CXCL4 and CXCL4/CTF, or antibodies against &#x003b1;v and &#x003b1;5&#x003b2;1 integrins, did not affect cell migration on collagen I, on which the cells migrated in a manner dependent on non-RGD binding &#x003b2;1 integrins (data not shown). Thus, immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin-dependent and -specific manners.</p></sec></sec><sec id="s3"><title>Discussion</title><p>We sought to assess whether CXCL4, a CXC chemokine that exhibit potent anti-angiogenic activities, and its C-terminus derived peptide CXCL4/CTF, would function as ligands for the integrin receptors on the surface of endothelial cells. We report here (<bold>1)</bold> that CXCL4 or CXCL4/CTF binds to &#x003b1;v&#x003b2;3 and to some extent to &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 integrins. (<bold>2)</bold> CXCL4 or CXCL4/CTF binding to integrins on the surface of &#x003b1;v&#x003b2;3-CHO and HUVECs is blocked by RGD peptide but not by RGE peptide. (<bold>3)</bold> The inactive peptide derived from CXCL4/CTF (CXCL4/CTF-S), fails to interact with integrins on the surface of &#x003b1;v&#x003b2;3-CHO or HUVECs. (<bold>4</bold>) Immobilized CXCL4 or CXCL4/CTF promotes &#x003b1;v&#x003b2;3-CHO and HUVEC cells spreading, focal adhesion and stress fibers formation and FAK phosphorylation (<bold>5)</bold> Functional studies show that immobilized CXCL4- or CXCL4/CTF support endothelial cells migration in an integrin-dependent manner and soluble CXCL4 or CXCL4/CTF, in turn, inhibits integrin-dependent endothelial cell migration.</p><p>Thus, the present study is the first to show that CXCL4 interacts with integrins. This interaction may constitute a novel mechanism for the inhibitory effects of CXCL4 on angiogenic blood vessels.</p><p>Several lines of cell biological and biochemical evidence demonstrated the interaction between CXCL4 and integrins in our study. Thus, inhibitory anti-integrin antibodies prevented &#x003b1;v&#x003b2;3-CHO and HUVEC cell attachment whereas CXCL4 interacted directly with purified &#x003b1;v&#x003b2;3 integrin in a specific manner in a solid-phase binding assay. Despite the fact that neither CXCL4 nor CXCL4/CTF contain an RGD sequence, the interaction of CXCL4 with integrins is divalent cation-dependent and is blocked by RGD peptide. Interestingly, a number of endogenous angiogenesis inhibitors such as endostatin <xref ref-type="bibr" rid="pone.0002657-Rehn1">&#x0005b;27&#x0005d;</xref>, arresten <xref ref-type="bibr" rid="pone.0002657-Sudhakar1">&#x0005b;35&#x0005d;</xref> canstatin <xref ref-type="bibr" rid="pone.0002657-Magnon1">&#x0005b;36&#x0005d;</xref> and tumstatin <xref ref-type="bibr" rid="pone.0002657-Sudhakar2">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Maeshima1">&#x0005b;38&#x0005d;</xref> also bind directly to integrin, despite the fact that they lack the RGD-binding site. For example, the interaction of endostatin with &#x003b1;5&#x003b2;1 integrin is inhibited by RGD peptide, however tumstatin binds to &#x003b1;v&#x003b2;3 in an RGD-independent manner. The fact that the interaction of CXCL4 with integrins is blocked by the RGD peptide indicates that CXCL4 interacts with the same or an overlapping RGD-binding site in integrin. Alternatively, it is possible that other amino acid sequences within CXCL4 also interact with the RGD binding site. Interestingly, CXCL4 and CXCL4/CTF both contain the NGR sequence that is known to interact with integrins, such as &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5 and &#x003b1;5&#x003b2;1 <xref ref-type="bibr" rid="pone.0002657-Koivunen1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Koivunen2">&#x0005b;40&#x0005d;</xref>. The NGR motif homes to the tumor vasculature, but not in normal endothelium, through its interaction with integrins. As a consequence, when coupled to anticancer drugs, the NGR peptide was shown to enhance their <italic>in vivo</italic> anti-tumor action and to reduce their toxicity <xref ref-type="bibr" rid="pone.0002657-Arap1">&#x0005b;41&#x0005d;</xref>. Additional studies are required to determine the sequence motif of CXCL4 that integrins recognize.</p><p>Our results show that immobilized CXCL4 or CXCL4/CTF supported cell spreading, focal adhesion and stress fibers formation and tyrosine phosphorylation (i.e., activation) of the focal adhesion kinase (FAK). These events are specific to integrin signaling <xref ref-type="bibr" rid="pone.0002657-Schwartz1">&#x0005b;21&#x0005d;</xref>. This indicates that immobilized CXCL4 or CXCL4/CTF activates postligand binding events downstream of integrins. The addition of two well-known integrin activators, Mn2&#x0002b; -acting as integrin activator from outside the cells (referred to as outside/in signaling)- and PMA -activating integrins from inside the cells via activation of PKC (referred to as inside/out signaling)-, produced a strong increase in both the number of attached cells and cell spreading on immobilized CXCL4 or CXCL4/CTF, comparable to fibrinogen. Thus, PF4 seems to bind to &#x003b1;v&#x003b2;3 integrins as a natural ligand of &#x003b1;v&#x003b2;3, such as fibrinogen, which binds with low affinity to unstimulated &#x003b1;v&#x003b2;3 and binds with high affinity to activated &#x003b1;v&#x003b2;3 upon stimulation by agonists, such as Mn2&#x0002b; or PMA <xref ref-type="bibr" rid="pone.0002657-Pampoori1">&#x0005b;29&#x0005d;</xref>. Thus, our finding suggests that interaction of CXCL4 or CXCL4/CTF to integrins is subject to integrin function regulation (i.e. affinity modulation). These results may be relevant to the antiangiogenic activity of CXCL4 in some pathophysiological circumstances in vivo. Indeed, it was shown that the basal activation state of &#x003b1;v&#x003b2;3 varies with the cell type and that an increase in the number of active &#x003b1;v&#x003b2;3 with high affinity for their ligands is correlated with the acquisition of cell malignancy <xref ref-type="bibr" rid="pone.0002657-Pampoori1">&#x0005b;29&#x0005d;</xref> and with the metastasis of some cancer, such as in human breast cancer <xref ref-type="bibr" rid="pone.0002657-FeldingHabermann1">&#x0005b;42&#x0005d;</xref>. Considering that the binding of CXCL4 to integrins depends on the integrin state (active or not), our results suggest that the binding of CXCL4 to endothelial cells should increase during pathological angiogenesis, where affinity modulation of integrins occurs.</p><p>Our results show that soluble CXCL4 or CXCL4/CTF inhibited endothelial cell adhesion to immobilized matrix proteins, as fibronectin or vitronectin. These results suggest that soluble CXCL4 or CXCL4/CTF act as antagonist for integrins &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1, to mediate its inhibition effect on -endothelial cells adhesion- angiogenesis. Theoretically, it is possible that CXCL4 could also act on attached endothelial cells by further promoting spreading. However, we clearly demonstrated that surface immobilized but not soluble CXCL4 promoted spreading. This finding argues against a similar effect on already attached cells. In addition, it is unlikely that spreading of already attached endothelial cells is inhibited by CXCL4, because of the strong binding of integrins to matrix proteins.</p><p>Although &#x003b1;5&#x003b2;1 is the most abundant integrin on HUVECS (<xref ref-type="fig" rid="pone-0002657-g005">Fig. 5A</xref>), adhesion experiments on immobilized CXCL4 in the presence of different blocking antibodies against &#x003b1;v&#x003b2;3, &#x003b1;5&#x003b2;1, &#x003b2;1, &#x003b1;5, &#x003b1;v, &#x003b2;3 may suggest a greater interaction of CXCL4 to &#x003b1;v&#x003b2;3 integrin (<xref ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>). However this conclusion must be interpreted with caution because these differences may also be due to more efficiency antibody binding to &#x003b1;v&#x003b2;3 than to &#x003b1;5&#x003b2;1. Also, a quantitative analysis comparing affinities is required to ascertain the potentially better interaction of CXCL4 to &#x003b1;v&#x003b2;3. Nevertheless, assuming that CXCL4 interacts better with &#x003b1;v&#x003b2;3 than &#x003b1;5&#x003b2;1, we may speculate that CXCL4 contains additional sequences for &#x003b1;v&#x003b2;3 interaction. The expression of both integrins &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 are significantly up-regulated on endothelial during angiogenesis. While &#x003b1;5&#x003b2;1 selectively recognizes primarily a single ECM protein ligand, fibronectin, &#x003b1;v&#x003b2;3 can bind several ligands such as vitronectin, fibronectin, fibrinogen, and other matrix proteins (13). The fact that CXCL4 may be a better ligand for &#x003b1;v&#x003b2;3 than &#x003b1;5&#x003b2;1, thus blocking the interaction of &#x003b1;v&#x003b2;3 integrin to its various ligands, may increase its inhibitory effect on angiogenesis.</p><p>To study the functional significance of the CXCL4-integrin interaction on angiogenesis, we examined the capacity of CXCL4 to modulate endothelial cell migration. We found that CXCL4 modulates endothelial cell migration, in an integrin-dependent and -specific manners. Cell migration is a vital step in the angiogenesis process and is governed by pro-angiogenic factors, such as VEGF and FGF, and integrins <xref ref-type="bibr" rid="pone.0002657-Davis1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-De1">&#x0005b;43&#x0005d;</xref>. Angiogenic stimulus by growth factors induces an increased expression of integrins in endothelial cells undergoing angiogenesis, thereby leading cells to spread, to migrate and to ultimately form new tubular vessels <xref ref-type="bibr" rid="pone.0002657-Davis1">&#x0005b;13&#x0005d;</xref>. Previous studies showed that both CXCL4 and CXCL4/CTF block endothelial cell migration in response to VEGF or FGF growth factors <xref ref-type="bibr" rid="pone.0002657-Hagedorn1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Yoshida1">&#x0005b;33&#x0005d;</xref>. This action is believed to mediate the anti-angiogenic effect of CXCL4, although its receptor mechanism was not characterized. Here we report that soluble CXCL4 or CXCL4/CTF, but not the inactive peptide CXCL4/CTF-S, inhibits endothelial cell migration in &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 in an integrin-dependent and -specific manners. Similarly, endostatin and thrombospondin-1, two endogenous angiogenesis inhibitors, inhibited endothelial cell migration through &#x003b2;1 integrins <xref ref-type="bibr" rid="pone.0002657-Rehn1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Short1">&#x0005b;44&#x0005d;</xref>. Our results suggest that integrins serve as functional receptors for CXCL4 to mediate its inhibition effect on -endothelial cells migration- angiogenesis. On the other hand, other data indicate that VEGF directly activates integrins and enhance cell migration mediated by &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 <xref ref-type="bibr" rid="pone.0002657-Byzova1">&#x0005b;34&#x0005d;</xref> Furthermore, FGF-2 stimulated endothelial cell migration mediated by &#x003b1;v&#x003b2;3 <xref ref-type="bibr" rid="pone.0002657-Ashton1">&#x0005b;45&#x0005d;</xref>. Further studies are needed to determine the potential significance of integrin-growth factor receptor cross-talk in CXCL4 action.</p><p>Previous studies showed that CXCL4 and its derived peptide CXCL4/CTF inhibit angiogenesis by interfering with the angiogenic effect of the growth factors FGF and VEGF165, either by directly binding to these angiogenic factors, thereby blocking their interaction with their specific receptors <xref ref-type="bibr" rid="pone.0002657-Lozano1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Perollet1">&#x0005b;46&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002657-Gengrinovitch1">&#x0005b;47&#x0005d;</xref>, or by competing with the binding of FGF or VEGF to heparan sulfate proteoglycans on the cell surface <xref ref-type="bibr" rid="pone.0002657-Perollet1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Sato1">&#x0005b;48&#x0005d;</xref>. Furthermore, CXCL4 was recently shown to bind to CXC3B, a chemokine receptor isoform that is present in some vascular beds <xref ref-type="bibr" rid="pone.0002657-Lasagni1">&#x0005b;49&#x0005d;</xref>. However, the role of CXC3-B receptors in the anti-angiogenic function of CXCL4 remains to be fully established <xref ref-type="bibr" rid="pone.0002657-Sulpice1">&#x0005b;50&#x0005d;</xref>. Our study suggests a novel additional mechanism for the antiangiogenic effects of CXCL4, which involves direct targeting of vessel through integrins. Since integrins are overexpressed in endothelial cells undergoing angiogenesis, this may explain why, in vivo, CXCL4 tends to preferentially target angiogenic blood vessels <xref ref-type="bibr" rid="pone.0002657-Hansell1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Borgstrom1">&#x0005b;20&#x0005d;</xref>. Furthermore, this targeting mechanism could be useful for selective treatments of cancer by CXCL4. Indeed and as mentioned above, peptides were shown to home selectively in tumor vasculature, through their interaction with integrins, and when coupled to anticancer drugs, they enhanced the <italic>in vivo</italic> anti-tumor action and reduced the toxicity of anticancer drugs <xref ref-type="bibr" rid="pone.0002657-Arap1">&#x0005b;41&#x0005d;</xref>. Finally, integrin-binding of CXCL4 or CXCL4/CTF is also consistent with a heparan sulfate proteoglycan-independent mechanism. Indeed, VEGF121, an endothelial cell mitogen that lacks heparin affinity, is inhibited by CXCL4 <xref ref-type="bibr" rid="pone.0002657-Gengrinovitch1">&#x0005b;47&#x0005d;</xref>. CXCL4 also antagonizes EGF-mediated endothelial cell proliferation independently from glycosaminoglycans <xref ref-type="bibr" rid="pone.0002657-Gentilini1">&#x0005b;51&#x0005d;</xref>.</p><p>In summary, a general picture of CXCL4's antiangiogenic mechanisms is emerging from the results described above. CXCL4 inhibits neovascularization <italic>in vivo</italic> by several distinct, although not necessarily exclusive, mechanisms including direct integrin binding&#x02013; reported here &#x02013;, direct interaction with angiogenic molecules <xref ref-type="bibr" rid="pone.0002657-Lozano1">&#x0005b;32&#x0005d;</xref>, binding to proteoheparan sulfate&#x02013;which acts as low affinity co-receptors for growth factors, such as FGF&#x02013;<xref ref-type="bibr" rid="pone.0002657-Perollet1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002657-Sato1">&#x0005b;48&#x0005d;</xref> or activation of CXCR3-B <xref ref-type="bibr" rid="pone.0002657-Lasagni1">&#x0005b;49&#x0005d;</xref>. These different mechanisms may operate in parallel and in function of the site and/or the type of vessel that undergo angiogenesis. Additional studies will be required to fully understand the significance of integrin binding and other mechanisms involved in CXCL4's antiangiogenic activity <italic>in vivo</italic>.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Reagents and Cell Culture</title><p>Fibronectin from human, plasma Fibrinogen from human plasma, poly-D-lysine and bovine serum albumin (BSA, fraction V) were purchased from Sigma. RGDS and RGES peptides were from Bachem, human purified platelet factor 4/CXCL4 (CXCL4) was obtained from Hyphen BioMed, France. C-terminal peptides of CXCL4, CXCL4/CTF (NGRKICLDLQAPLYKKIIKKLLES) or CXCL4/CTF-S (LGLKPLKQELIAYRDNK IKSICLK) were purchased from ThermoHybaid (Ulm, Germany). Purified integrins and the purified monoclonal anti-human integrin antibodies LM609 (anti-&#x003b1;v&#x003b2;3), P1F6 (anti-&#x003b1;v&#x003b2;5), JBS5 and HA5 (anti-&#x003b1;5&#x003b2;1), B3A (anti-&#x003b2;3), AV1 (anti-&#x003b1;v), CD29 (anti-&#x003b2;1), P1D6 (anti-&#x003b1;5) were purchased from Chemicon. Mouse Ig1 antibody was purchased from Chemicon. Peroxidase and FITC (Fluorescein isothiocyanate) conjugated goat anti-mouse immunoglobulins were purchased from DAKO. Mouse monoclonal anti-human vinculin antibody was from Sigma and Rhodamin-Phalloidin from Molecular probes. The Chinese hamster ovary (CHO) cell line CRL9096, as well as CHO clones expressing human &#x003b1;v&#x003b2;3 integrin (&#x003b1;v&#x003b2;3-CHO, A06) were established as described (25). Cells lines were grown at 37&#x000b0;C, 5&#x00025; CO2 in Dublecco's Modified Eagle Medium (GIBCO) supplemented with 10&#x00025; foetal bovine serum, 2 mM glutamine, penicillin and streptomycin (100 UI/ml) and 1&#x00025; non-essential amino acids. Human umbilical vein endothelial cells (HUVECs, Clonetics) were cultured in EGM medium (Cambrex) supplemented with 10&#x00025; foetal bovine serum, 2 mM glutamine, and penicillin and streptomycin (100 UI/ml). Experimentation was carried out at cell passage number 4&#x02013;10.</p></sec><sec id="s4b"><title>Flow Cytometry</title><p>Analysis cell-surface integrin expression was performed as described <xref ref-type="bibr" rid="pone.0002657-Pampoori1">&#x0005b;29&#x0005d;</xref>. Cells were suspended in incubation Walsh buffer (137 mM NaCl, 2.7 mM KCL, 3.3 mM NaH<sub>2</sub>PO<sub>4</sub>, 3.8 mM HEPES, 1 mM MgCl2, 5.5 mM glucose, and 1 mg/ml BSA, pH 7.4) and 2&#x000d7;10<sup>5</sup> cells incubated for 30 min on ice with a monoclonal antibody (10 &#x000b5;g/ml) specific for &#x003b1;v&#x003b2;3 (LM609), or &#x003b1;v&#x003b2;5 (P1F6), or &#x003b1;5&#x003b2;1 (HA5). After washing, the cells were incubated for 20 min on ice with FITC-conjugated goat anti-mouse IgG, washed again, and analyzed on a FACSCalibur flow cytometer (Becton Dickinson Biosciences). As a negative control, samples were incubated with the secondary antibody alone.</p></sec><sec id="s4c"><title>Cell Attachment Assay</title><p>Cell attachment was assayed as described <xref ref-type="bibr" rid="pone.0002657-Wickstrm1">&#x0005b;52&#x0005d;</xref>. Microtiter wells (Immulon 2, ThermoLabsystems) were coated for 2 h at 37&#x000b0;C with the indicated concentrations of proteins. The wells were blocked for 1 h with 1&#x00025; BSA in PBS. Cells were briefly trypsinized followed by washes with serum-containing medium and serum-free medium containing 0,5&#x00025; BSA. Cells were suspended in 3,5&#x000d7;10<sup>5</sup> cells/ml in serum-free medium containing 0,5&#x00025; BSA and incubated in the presence or absence of 10 mM EDTA, 25 &#x000b5;g/ml RGD, RGE peptides or 10 &#x000b5;g/ml of anti-integrin antibodies for 15 min at room temperature. To inhibit adhesion on various ECMs proteins with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior plating onto wells, as indicated in the figures. 100 &#x000b5;l of cells suspensions were added to the coated wells, and the plates were incubated at 37&#x000b0;C for 60 min. Non attached cells were removed by washing with PBS and then fixed and stained in 30&#x00025; methanol, 10&#x00025; acetic acid, containing 0,1&#x00025; Coomassie blue. After extensive washing, the cells were lysed in 1&#x00025; SDS, after which the amount of lysed cells were quantified by measuring their absorbance at 620 nm. Background absorbance observed in the wells coated with BSA was deducted from the values obtained. Each time point represented three independent experiments performed in triplicate.</p></sec><sec id="s4d"><title>Solid-Phase Ligand-Binding Assay</title><p>Solid-phase ligand binding assay was performed as described previously with minor modifications <xref ref-type="bibr" rid="pone.0002657-Rehn1">&#x0005b;27&#x0005d;</xref>. Immulon 2 microtiter wells were coated with 25 &#x000b5;g/ml CXCL4 or CXCL4/CTF in PBS overnight at 4&#x000b0;C. The wells were blocked with 1&#x00025; BSA in walsh buffer at room temperature for 1 h. Octylglucoside &#x003b1;v&#x003b2;3 integrin was added on coated wells and incubated for 2 h at 37&#x000b0;C. Unbound integrin molecules were extensively washed with walsh buffer containing 0,05&#x00025; Tween 20. The bound integrin molecules were incubated with 1/1000 dilution of a polyclonal anti-&#x003b1;v cytoplasmic domain antibody (Chemicon) for 1 h at room temperature. After extensive washes with walsh buffer-0,05&#x00025; Tween 20, the bound antibodies were detected by using Peroxidase-Conjugated goat anti-rabbit IgG (Dako). TMB liquid substrate (sigma) was added to the wells, the reactions were stopped with 0,5 M H<sub>2</sub>SO<sub>4</sub>, and absorbance was measured at 450 nm. Background absorbance in the wells coated with BSA was deducted from the values obtained.</p></sec><sec id="s4e"><title>Cell Spreading and Confocal Microscopy Analysis</title><p>Cells were washed twice with serum-free medium, suspended to the serum-free medium, and plated on coverslips that had been coated with (25 &#x000b5;g/ml) CXCL4, (25 &#x000b5;g/ml) CXCL4/CTF, (25 &#x000b5;g/ml) CXCL4/CTF-S, (100 &#x000b5;g/ml) fibrinogen and (100 &#x000b5;g/ml) poly-D-lysine and incubated at 37&#x000b0;C for 4 h. After removing nonadherent cells, the adherent cells were fixed in 4&#x00025; parafolmaldehyde, permeabilized with 0,2&#x00025; Triton X-100 in PBS, and stained with monoclonal anti-vinculin antibody, FITC-anti-mouse IgG and rhodamine-phalloidin <xref ref-type="bibr" rid="pone.0002657-Shiraga1">&#x0005b;53&#x0005d;</xref>. Cells were analyzed by confocal laser scanning microscopy and photomicrographs were prepared using Adobe Photoshop 8.</p></sec><sec id="s4f"><title>Analysis of Tyrosine Phosphorylation of FAK</title><p>Tyrosine Phosphorylation of FAK was assayed as described <xref ref-type="bibr" rid="pone.0002657-Gao1">&#x0005b;54&#x0005d;</xref>. HUVECs were plated for 60 min on dishes that had been coated with 5 mg/ml of BSA or (100 &#x000b5;g/ml) fibrinogen or (25 &#x000b5;g/ml) CXCL4 or (25 &#x000b5;g/ml) CXCL4/CTF or (100 &#x000b5;g/ml) poly-D-lysine. After 60 min, non-adherent cells from BSA-coated plates were diluted 1:1 with PBS, sedimented at 100 g for 5 min and washed once with PBS before lysis in complete RIPA buffer (1&#x00025; Triton X-100, 1&#x00025; sodium deoxycholate, 0.1&#x00025; SDS, 158 mM NaCl, 10 mM Tris, pH 7.4, 1 mM Na<sub>2</sub>EGTA, 1 mM sodium vanadate, 0.5 mM leupeptin, 0.25 mg/ml pefabloc, 5 mg/ml aprotinin). The adherent cells from plates coated with fibrinogen or CXCL4 or CXCL4/CTF were rinsed twice with PBS, lysed on the plates with ice-cold complete RIPA buffer and scrapped into microcentrifuge tubes. Lysates were incubated for 30 min on ice and clarified supernatants for immunoprecipitation. Equal amounts of protein from each lysate (200 &#x000b5;g of protein) were immunoprecipitated with rabbit antiserum specific for FAK (Santa Cruz). One half of immunoprecipitates were subjected to western blotting with anti-phosphotyrosine mAbs, 4G10 (BD Transduction Laboratories) and PY20 (Upstate Biotechnology), and the other half was probed with mAb anti-FAK (BD Transduction Laboratories). Immunoreactive bands were detected by enhanced cheminuluminescence detection.</p></sec><sec id="s4g"><title>Endothelial cell Migration</title><p>Haptotactic cell motility was measured by using a modified Boyden chamber (BD, Falcon) as previously described <xref ref-type="bibr" rid="pone.0002657-Leavesley1">&#x0005b;22&#x0005d;</xref>. The undersurface of the membrane filter was coated with 25 &#x000b5;g/ml of CXCL4 or 25 &#x000b5;g/ml CXCL4/CTF or various matrix proteins. After washing the membranes with PBS, nonspecific adhesion sites were saturated with 1&#x00025; BSA at 22&#x000b0;C for 1 h. HUVECs (3&#x000d7;10<sup>4</sup>) were added to the upper chambers in serum-free medium and were allowed to migrate to the underside of the chamber for 4 h at 37&#x000b0;C. Cell migration was measured after 4 h of incubation at 37&#x000b0;C. All non migrated cells were removed from the upper face of the membrane filter with the cotton swab and cells migrated to the lower face were fixed and stained in 30&#x00025; methanol, 10&#x00025; acetic acid, containing 0,1&#x00025; Coomassie blue. Subsequently, the number of stained migrated cells (to the lower face of the membrane filter) was counted. Migration results are expressed in terms of the average number of cells/high-magnification microscopic field. To inhibit migration on CXCL4 or CXCL4/CTF, cells with pretreated with 10 &#x000b5;g/ml of anti-integrin antibodies for 30 min in suspension prior to plated in chambers. To inhibit migration on various matrix proteins with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior adding to the upper chambers, as indicated in the figures. In chemotactic cell motility experiments, VEGF (5 ng/ml) was added in the lower chambers. To inhibit migration on fibronectin to VEGF with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior adding to the upper chambers. In all experiments, nonspecific migration was determined using BSA as a ligand and was subtracted from the values of relative cell migration obtained on different matrix proteins.</p></sec><sec id="s4h"><title>Statistical Analysis</title><p>Student's test was used to determine the significance of differences.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0002657.s001"><label>Figure S1</label><caption><p>Soluble CXCL4 or CXCL4/CTF inhibits cell adhesion to fibronectin and vitronectin. HUVECs and &#x003b1;v&#x003b2;3-CHO adhesion on immobilized (10 &#x000b5;g/ml) fibronectin or (10 &#x000b5;g/ml) vitronectin was determined in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S as described in <xref ref-type="sec" rid="s4">Material and Methods</xref>. Error bars represent the mean&#x0002b;SD, #, P&#x0003c;0.005; &#x0002a;, P&#x0003c;0.001 compared to the cell adhesion in the absence of CXCL4 or CXCL4/CTF; n&#x0200a;&#x0003d;&#x0200a;2 independent experiments.</p><p>(39.08 MB DOC)</p></caption><media xlink:href="pone.0002657.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank Pr Martin A. Schwartz (University of Virginia, Charlottesville, United State) and Dr Serge Ahmed (Universit&#x000e9; Victor-Segalen Bordeaux 2) for critically reading the manuscript, Dr Alan Nurden (University Bordeaux II, France) for helpful discussion and Dr Francesca De Giorgi-Ichas, (INSERM U916-Institut Bergoni&#x000e9;, Bordeaux) for helpful technical assistance for confocal analysis. This work is dedicated to Aicha Mekki-Aidoudi and Bechir Aidoudi.</p></ack><ref-list><title>References</title><ref id="pone.0002657-Folkman1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>1995</year><article-title>Angiogenesis in cancer, vascular rheumatoid and other disease.</article-title><source>Nat Med</source><volume>1</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">7584949</pub-id></citation></ref><ref id="pone.0002657-Folkman2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>1971</year><article-title>Tumor angiogensis: therapeutic implications.</article-title><source>N Engl J Med</source><volume>285</volume><fpage>1182</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">4938153</pub-id></citation></ref><ref id="pone.0002657-Folkman3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Angiogenesis: an organizing principle for drug discovery?</article-title><source>Nat Rev Drug Discov</source><volume>6</volume><fpage>273</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">17396134</pub-id></citation></ref><ref id="pone.0002657-Levine1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>SP</given-names></name><name><surname>Wohl</surname><given-names>H</given-names></name></person-group><year>1976</year><article-title>Human p1atelet factor 4: Purification and characterization by affinity chromatography.</article-title><source>J Biol Chem</source><volume>51</volume><fpage>324</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">812871</pub-id></citation></ref><ref id="pone.0002657-Maione1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maione</surname><given-names>TE</given-names></name><name><surname>Gray</surname><given-names>GS</given-names></name><name><surname>Petro</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>AJ</given-names></name><name><surname>Donner</surname><given-names>AL</given-names></name><etal/></person-group><year>1990</year><article-title>Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.</article-title><source>Science</source><volume>247</volume><fpage>77</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1688470</pub-id></citation></ref><ref id="pone.0002657-Jouan1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jouan</surname><given-names>V</given-names></name><name><surname>Canron</surname><given-names>X</given-names></name><name><surname>Alemany</surname><given-names>M</given-names></name><name><surname>Caen</surname><given-names>JP</given-names></name><name><surname>Quentin</surname><given-names>G</given-names></name><etal/></person-group><year>1999</year><article-title>Modulation of <italic>in vitro</italic> angiogenesis by platelet factor-4 derived peptides and mechanism of action.</article-title><source>Blood</source><volume>94</volume><fpage>984</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">10419890</pub-id></citation></ref><ref id="pone.0002657-Hagedorn1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagedorn</surname><given-names>M</given-names></name><name><surname>Zilberberg</surname><given-names>L</given-names></name><name><surname>Lozano</surname><given-names>RM</given-names></name><name><surname>Cuevas</surname><given-names>P</given-names></name><name><surname>Canron</surname><given-names>X</given-names></name><etal/></person-group><year>2001</year><article-title>A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.</article-title><source>FASEB J</source><volume>15</volume><fpage>550</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">11259363</pub-id></citation></ref><ref id="pone.0002657-Sharpe1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>RJ</given-names></name><name><surname>Byers</surname><given-names>HR</given-names></name><name><surname>Scott</surname><given-names>CF</given-names></name><name><surname>Bauer</surname><given-names>SI</given-names></name><name><surname>Maione</surname><given-names>TE</given-names></name></person-group><year>1990</year><article-title>Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4.</article-title><source>J Natl Cancer Inst</source><volume>82</volume><fpage>848</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1692094</pub-id></citation></ref><ref id="pone.0002657-Tanaka1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Manome</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>P</given-names></name><name><surname>Kufe</surname><given-names>DW</given-names></name><name><surname>Fine</surname><given-names>HA</given-names></name></person-group><year>1997</year><article-title>Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.</article-title><source>Nat Med</source><volume>3</volume><fpage>437</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9095178</pub-id></citation></ref><ref id="pone.0002657-Maione2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maione</surname><given-names>TE</given-names></name><name><surname>Gray</surname><given-names>GS</given-names></name><name><surname>Hunt</surname><given-names>AJ</given-names></name><name><surname>Sharpe</surname><given-names>RJ</given-names></name></person-group><year>1991</year><article-title>Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.</article-title><source>Cancer Res</source><volume>51</volume><fpage>2077</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">1706960</pub-id></citation></ref><ref id="pone.0002657-Bello1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bello</surname><given-names>L</given-names></name><name><surname>Giussani</surname><given-names>C</given-names></name><name><surname>Carrabba</surname><given-names>G</given-names></name><name><surname>Pluderi</surname><given-names>M</given-names></name><name><surname>Lucini</surname><given-names>V</given-names></name><etal/></person-group><year>2002</year><article-title>Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors.</article-title><source>Clin Cancer Res</source><volume>8</volume><fpage>3539</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">12429645</pub-id></citation></ref><ref id="pone.0002657-Kolber1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolber</surname><given-names>DL</given-names></name><name><surname>Knisely</surname><given-names>TL</given-names></name><name><surname>Maione</surname><given-names>TE</given-names></name></person-group><year>1995</year><article-title>Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.</article-title><source>J Natl Cancer Inst</source><volume>87</volume><fpage>304</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7707422</pub-id></citation></ref><ref id="pone.0002657-Davis1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>GE</given-names></name><name><surname>Senger</surname><given-names>DR</given-names></name></person-group><year>2005</year><article-title>Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization.</article-title><source>Circ Res</source><volume>97</volume><fpage>1093</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">16306453</pub-id></citation></ref><ref id="pone.0002657-Brooks1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>PC</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><year>1994a</year><article-title>Requirement of vascular integrin &#x003b1;v&#x003b2;3 for angiogenesis.</article-title><source>Science</source><volume>264</volume><fpage>569</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7512751</pub-id></citation></ref><ref id="pone.0002657-Brooks2"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>PC</given-names></name><name><surname>Montgomery</surname><given-names>AM</given-names></name><name><surname>Rosenfeld</surname><given-names>M</given-names></name><name><surname>Reisfeld</surname><given-names>RA</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><etal/></person-group><year>1994b</year><article-title>Integrin &#x003b1;v&#x003b2;3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.</article-title><source>Cell</source><volume>79</volume><fpage>1157</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">7528107</pub-id></citation></ref><ref id="pone.0002657-Friedlander1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Brooks</surname><given-names>PC</given-names></name><name><surname>Shaffer</surname><given-names>RW</given-names></name><name><surname>Kincaid</surname><given-names>CM</given-names></name><name><surname>Varner</surname><given-names>JA</given-names></name><etal/></person-group><year>1995</year><article-title>Definition of two angiogenic pathways by distinct alpha v integrins.</article-title><source>Science</source><volume>270</volume><fpage>1500</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">7491498</pub-id></citation></ref><ref id="pone.0002657-Kim1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Mousa</surname><given-names>SA</given-names></name><name><surname>Varner</surname><given-names>JA</given-names></name></person-group><year>2000</year><article-title>Regulation of angiogenesis <italic>in vivo</italic> by ligation of integrin &#x003b1;5&#x003b2;1 with the central cell-binding domain of fibronectin.</article-title><source>Am J Pathol</source><volume>156</volume><fpage>1345</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10751360</pub-id></citation></ref><ref id="pone.0002657-Fukami1"><label>18</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fukami</surname><given-names>MH</given-names></name><name><surname>Holmsen</surname><given-names>H</given-names></name><name><surname>Kowalska</surname><given-names>MA</given-names></name><name><surname>Niewiarowski</surname><given-names>S</given-names></name></person-group><year>2001</year><article-title>Platelet secretion.</article-title><person-group person-group-type="editor"><name><surname>Colman</surname><given-names>RW</given-names></name></person-group><source>Hemostasis and Thrombosis. Basis Principles and Clinical Practice</source><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wikins</publisher-name><fpage>561</fpage><lpage>573</lpage></citation></ref><ref id="pone.0002657-Hansell1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansell</surname><given-names>P</given-names></name><name><surname>Maione</surname><given-names>TE</given-names></name><name><surname>Borgstrom</surname><given-names>P</given-names></name></person-group><year>1995</year><article-title>Selective binding of platelet factor 4 to regions of active angiogenesis <italic>in vivo</italic>.</article-title><source>Am J Physiol</source><volume>269</volume><fpage>829</fpage><lpage>36</lpage></citation></ref><ref id="pone.0002657-Borgstrom1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borgstrom</surname><given-names>P</given-names></name><name><surname>Discipio</surname><given-names>R</given-names></name><name><surname>Maione</surname><given-names>TE</given-names></name></person-group><year>1998</year><article-title>Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma.</article-title><source>Anticancer Res</source><volume>18</volume><fpage>4035</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">9891442</pub-id></citation></ref><ref id="pone.0002657-Schwartz1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Schaller</surname><given-names>MD</given-names></name><name><surname>Ginsberg</surname><given-names>MH</given-names></name></person-group><year>1995</year><article-title>Integrins: emerging paradigms of signal transduction.</article-title><source>Annu Rev Cell Dev Biol</source><volume>11</volume><fpage>549</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">8689569</pub-id></citation></ref><ref id="pone.0002657-Leavesley1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leavesley</surname><given-names>DI</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Rosenfeld</surname><given-names>M</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><year>1993</year><article-title>Integrin &#x003b2;1- and &#x003b2;3-mediated endothelial cell migration is triggered through distinct signaling mechanisms.</article-title><source>J Cell Biol</source><volume>121</volume><fpage>163</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">7681432</pub-id></citation></ref><ref id="pone.0002657-Stromblad1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stromblad</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>JC</given-names></name><name><surname>Yebra</surname><given-names>M</given-names></name><name><surname>Brooks</surname><given-names>PC</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><year>1996</year><article-title>Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin &#x003b1;v&#x003b2;3 during angiogenesis.</article-title><source>J Clin Invest</source><volume>98</volume><fpage>426</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8755653</pub-id></citation></ref><ref id="pone.0002657-Hsu1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>AR</given-names></name><name><surname>Veeravagu</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>LC</given-names></name><name><surname>Tse</surname><given-names>V</given-names></name><etal/></person-group><year>2007</year><article-title>Integrin alpha (v)beta (3) antagonists for anti-angiogenic cancer treatment.</article-title><source>Recent Patents Anticancer Drug Discov</source><volume>2</volume><fpage>143</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">18221059</pub-id></citation></ref><ref id="pone.0002657-Pasco1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasco</surname><given-names>S</given-names></name><name><surname>Monboisse</surname><given-names>JC</given-names></name><name><surname>Kieffer</surname><given-names>N</given-names></name></person-group><year>2000</year><article-title>The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin &#x003b1;v&#x003b2;3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>32999</fpage><lpage>33007</lpage><pub-id pub-id-type="pmid">10934203</pub-id></citation></ref><ref id="pone.0002657-Humphries1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>MJ</given-names></name></person-group><year>1996</year><article-title>Integrin activation: the link between ligand binding and signal transduction.</article-title><source>Curr Opin Cell Biol</source><volume>8</volume><fpage>632</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8939662</pub-id></citation></ref><ref id="pone.0002657-Rehn1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rehn</surname><given-names>M</given-names></name><name><surname>Veikkola</surname><given-names>T</given-names></name><name><surname>Kukk-Valdre</surname><given-names>E</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Ilmonen</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Interaction of endostatin with integrins implicated in angiogenesis.</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>1024</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">11158588</pub-id></citation></ref><ref id="pone.0002657-Trikha1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trikha</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Timar</surname><given-names>J</given-names></name><name><surname>Raso</surname><given-names>E</given-names></name><name><surname>Kennel</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Multiple roles for platelet GPIIb/IIIa and &#x003b1;v&#x003b2;3 integrins in tumor growth, angiogenesis, and metastasis.</article-title><source>Cancer Research</source><volume>62</volume><fpage>2824</fpage><lpage>2833</lpage><pub-id pub-id-type="pmid">12019160</pub-id></citation></ref><ref id="pone.0002657-Pampoori1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pampoori</surname><given-names>N</given-names></name><name><surname>Hato</surname><given-names>T</given-names></name><name><surname>Stupack</surname><given-names>DG</given-names></name><name><surname>Aidoudi</surname><given-names>S</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name><etal/></person-group><year>1999</year><article-title>Mechanisms and consequences of affinity modulation of integrin &#x003b1;v&#x003b2;3 detected with a novel patch-enginered monovalent ligand.</article-title><source>J Biol Chem</source><volume>274</volume><fpage>21609</fpage><lpage>21616</lpage><pub-id pub-id-type="pmid">10419468</pub-id></citation></ref><ref id="pone.0002657-Vuori1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vuori</surname><given-names>K</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><year>1993</year><article-title>Activation of protein kinase C precedes &#x003b1;5&#x003b2;1 integrin-mediated cell spreading on fibronectin.</article-title><source>J Biol Chem</source><volume>268</volume><fpage>21459</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">7691809</pub-id></citation></ref><ref id="pone.0002657-Mould1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>AP</given-names></name><name><surname>Akiyama</surname><given-names>SK</given-names></name><name><surname>Humphries</surname><given-names>MJ</given-names></name></person-group><year>1995</year><article-title>Regulation of integrin &#x003b1;5&#x003b2;1-fibronectin interactions by divalent cations. Evidence for distinct classes of binding sites for Mn2&#x0002b;, Mg2&#x0002b;, and Ca2&#x0002b;.</article-title><source>J Biol Chem</source><volume>270</volume><fpage>26270</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7592835</pub-id></citation></ref><ref id="pone.0002657-Lozano1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>RM</given-names></name><name><surname>Redondo-Horcajo</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>MA</given-names></name><name><surname>Zilberberg</surname><given-names>L</given-names></name><name><surname>Cuevas</surname><given-names>P</given-names></name><etal/></person-group><year>2001</year><article-title>Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>35723</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11423536</pub-id></citation></ref><ref id="pone.0002657-Yoshida1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Anand-Apte</surname><given-names>B</given-names></name><name><surname>Zetter</surname><given-names>BR</given-names></name></person-group><year>1996</year><article-title>Differential Endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.</article-title><source>Growth Factors</source><volume>13</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8962720</pub-id></citation></ref><ref id="pone.0002657-Byzova1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Byzova</surname><given-names>TV</given-names></name><name><surname>Goldman</surname><given-names>CK</given-names></name><name><surname>Pampori</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>KA</given-names></name><name><surname>Bett</surname><given-names>A</given-names></name><etal/></person-group><year>2000</year><article-title>A mechanism for modulation of cellular responses to VEGF: activation of the integrins.</article-title><source>Mol Cell</source><volume>6</volume><fpage>851</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11090623</pub-id></citation></ref><ref id="pone.0002657-Sudhakar1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sudhakar</surname><given-names>A</given-names></name><name><surname>Nyberg</surname><given-names>P</given-names></name><name><surname>Keshamouni</surname><given-names>VG</given-names></name><name><surname>Mannam</surname><given-names>AP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by &#x003b1;1&#x003b2;1 integrin.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>2801</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16151532</pub-id></citation></ref><ref id="pone.0002657-Magnon1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnon</surname><given-names>C</given-names></name><name><surname>Galaup</surname><given-names>A</given-names></name><name><surname>Mullan</surname><given-names>B</given-names></name><name><surname>Rouffiac</surname><given-names>V</given-names></name><name><surname>Bouquet</surname><given-names>C</given-names></name><etal/></person-group><year>2005</year><article-title>Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with &#x003b1;v&#x003b2;3 and &#x003b1;v&#x003b2;5 integrins.</article-title><source>Cancer Res</source><volume>65</volume><fpage>4353</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15899827</pub-id></citation></ref><ref id="pone.0002657-Sudhakar2"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sudhakar</surname><given-names>A</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Lively</surname><given-names>J</given-names></name><name><surname>Zeisberg</surname><given-names>L</given-names></name><etal/></person-group><year>2003</year><article-title>Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by &#x003b1;v&#x003b2;3 and &#x003b1;5&#x003b2;1 integrins.</article-title><source>Proc Natl Acad Sci USA</source><volume>100</volume><fpage>4766</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12682293</pub-id></citation></ref><ref id="pone.0002657-Maeshima1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeshima</surname><given-names>Y</given-names></name><name><surname>Sudhakar</surname><given-names>A</given-names></name><name><surname>Lively</surname><given-names>JC</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.</article-title><source>Science</source><volume>295</volume><fpage>140</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11778052</pub-id></citation></ref><ref id="pone.0002657-Koivunen1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koivunen</surname><given-names>E</given-names></name><name><surname>Gay</surname><given-names>DA</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><year>1993</year><article-title>Selection of peptides binding to the &#x003b1;5&#x003b2;1 integrin from phage display library.</article-title><source>J Biol Chem</source><volume>268</volume><fpage>20205</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">7690752</pub-id></citation></ref><ref id="pone.0002657-Koivunen2"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koivunen</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><year>1994</year><article-title>Isolation of a highly specific ligand for the &#x003b1;5&#x003b2;1 integrin from a phage display library.</article-title><source>J Cell Biol</source><volume>124</volume><fpage>373</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">7507494</pub-id></citation></ref><ref id="pone.0002657-Arap1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><year>1998</year><article-title>Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.</article-title><source>Science</source><volume>279</volume><fpage>377</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9430587</pub-id></citation></ref><ref id="pone.0002657-FeldingHabermann1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Felding-Habermann</surname><given-names>B</given-names></name><name><surname>O'Toole</surname><given-names>TE</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Fransvea</surname><given-names>E</given-names></name><name><surname>Ruggeri</surname><given-names>Z</given-names></name><etal/></person-group><year>2001</year><article-title>Integrin activation controls metastasis in human breast cancer.</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>1853</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11172040</pub-id></citation></ref><ref id="pone.0002657-De1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>S</given-names></name><name><surname>Razorenova</surname><given-names>O</given-names></name><name><surname>McCabe</surname><given-names>NP</given-names></name><name><surname>O'Toole</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Byzova</surname><given-names>TV</given-names></name></person-group><year>2005</year><article-title>VEGF-integrin interplay controls tumor growth and vascularization.</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>7589</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15897451</pub-id></citation></ref><ref id="pone.0002657-Short1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>SM</given-names></name><name><surname>Derrien</surname><given-names>A</given-names></name><name><surname>Narsimhan</surname><given-names>RP</given-names></name><name><surname>Lawler</surname><given-names>J</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name><etal/></person-group><year>2005</year><article-title>Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by &#x003b2;1 integrins.</article-title><source>J Cell Biol</source><volume>168</volume><fpage>643</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15716381</pub-id></citation></ref><ref id="pone.0002657-Ashton1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashton</surname><given-names>AW</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Helisch</surname><given-names>A</given-names></name><name><surname>Ware</surname><given-names>JA</given-names></name></person-group><year>2004</year><article-title>Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and &#x003b1;v&#x003b2;3.</article-title><source>Circ Res</source><volume>94</volume><fpage>735</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">14963009</pub-id></citation></ref><ref id="pone.0002657-Perollet1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perollet</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>ZC</given-names></name><name><surname>Savona</surname><given-names>C</given-names></name><name><surname>Caen</surname><given-names>JP</given-names></name><name><surname>Bikfalvi</surname><given-names>A</given-names></name></person-group><year>1998</year><article-title>Platelet factor-4 modulates fibroblast growth factor-2 activity and inhibits FGF-2 dimerization.</article-title><source>Blood</source><volume>91</volume><fpage>3289</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">9558385</pub-id></citation></ref><ref id="pone.0002657-Gengrinovitch1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gengrinovitch</surname><given-names>S</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Gitay-Goren</surname><given-names>H</given-names></name><name><surname>Rockwell</surname><given-names>P</given-names></name><etal/></person-group><year>1995</year><article-title>Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.</article-title><source>J Biol Chem</source><volume>270</volume><fpage>15059</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7797488</pub-id></citation></ref><ref id="pone.0002657-Sato1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Takaki</surname><given-names>R</given-names></name></person-group><year>1990</year><article-title>Platelet factor-4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells.</article-title><source>Biochem Biophys Res Commun</source><volume>172</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">2173572</pub-id></citation></ref><ref id="pone.0002657-Lasagni1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lasagni</surname><given-names>L</given-names></name><name><surname>Francalanci</surname><given-names>M</given-names></name><name><surname>Annunziato</surname><given-names>F</given-names></name><name><surname>Lazzeri</surname><given-names>E</given-names></name><name><surname>Giannini</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.</article-title><source>J Exp Med</source><volume>197</volume><fpage>1537</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">12782716</pub-id></citation></ref><ref id="pone.0002657-Sulpice1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulpice</surname><given-names>E</given-names></name><name><surname>Contreres</surname><given-names>JO</given-names></name><name><surname>Lacour</surname><given-names>J</given-names></name><name><surname>Bryckaert</surname><given-names>M</given-names></name><name><surname>Tobelem</surname><given-names>G</given-names></name></person-group><year>2004</year><article-title>Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms.</article-title><source>Eur J Biochem</source><volume>271</volume><fpage>3310</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15291808</pub-id></citation></ref><ref id="pone.0002657-Gentilini1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gentilini</surname><given-names>G</given-names></name><name><surname>Kirschbaum</surname><given-names>NE</given-names></name><name><surname>Augustine</surname><given-names>JA</given-names></name><name><surname>Aster</surname><given-names>RH</given-names></name><name><surname>Visentin</surname><given-names>GP</given-names></name></person-group><year>1999</year><article-title>Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (CXCL4), is associated with impaired downregulation of p21(Cip1/WAF1).</article-title><source>Blood</source><volume>93</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9864142</pub-id></citation></ref><ref id="pone.0002657-Wickstrm1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wickstr&#x000f6;m</surname><given-names>SA</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><name><surname>Keski-Oja</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells.</article-title><source>J Biol Chem.</source><volume>279</volume><fpage>20178</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">14973128</pub-id></citation></ref><ref id="pone.0002657-Shiraga1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiraga</surname><given-names>M</given-names></name><name><surname>Richie</surname><given-names>A</given-names></name><name><surname>Aidoudi</surname><given-names>S</given-names></name><name><surname>Baron</surname><given-names>V</given-names></name><name><surname>Wilcox</surname><given-names>D</given-names></name><etal/></person-group><year>1999</year><article-title>Primary megakaryoctes reveal a role for transcription factor NF-E2 in integrin &#x003b1;IIb&#x003b2;3 signaling.</article-title><source>J Cell Biol</source><volume>147</volume><fpage>1419</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">10613901</pub-id></citation></ref><ref id="pone.0002657-Gao1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Zoller</surname><given-names>KE</given-names></name><name><surname>Ginsberg</surname><given-names>MH</given-names></name><name><surname>Brugge</surname><given-names>JS</given-names></name><name><surname>Shattil</surname><given-names>SJ</given-names></name></person-group><year>1997</year><article-title>Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3.</article-title><source>EMBO J</source><volume>16</volume><fpage>6414</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9351824</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work has been supported by grants from the &#x0201c;Agence Nationale de la Recherche (ANR)&#x0201d;, the National French Cancer Institute (INCA), &#x0201c;the Ligue Nationale du Cancer&#x0201d; and the &#x0201c;Association pour la Recherche sur le Cancer (ARC)&#x0201d; to A.B. The sponsors had no role in designing the study or approving the manuscript.</p></fn></fn-group></back></article> 